Company: DAWN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001193125-25-264649
Chunk: 116

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Item 3
Chunk 116
---
 status of our clinical trials; •changes in the development status of our product candidates, including variations in the level of expense related to the development of our programs or funding support by us or by existing or future collaborators or licensing partners; •regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our business; •the success of competitive products or technologies; •introductions and announcements of new product candidates by us, our future collaboration partners, or our competitors, and the timing of these introductions or announcements; •actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; •our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; •actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; •the success of our efforts to acquire or in-license additional technologies or product candidates; •announced or completed significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; •developments or disputes concerning our intellectual property and proprietary rights; •the recruitment or departure of key personnel; •changes in the structure of healthcare payment systems; •actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally; •our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market; •speculation in the press or investment community; 

93

•share price and fluctuations of trading volume of our common stock;•the impact of interest rate increases on the overall stock market and the market for biopharmaceutical company stocks;•fluctuations in the valuation of companies perceived by investors to be comparable to us; •sales of shares of our common stock by us, insiders or our stockholders; •our ability or inability to raise additional capital and the terms on which we raise it; •the concentrated ownership of our common stock; •changes in accounting principles; •natural disasters and other calamities;•general economic, industry and market conditions, including inflation, changes in interest rates, changes in domestic and foreign currency rates and significant political or regulatory developments or changes in trade policy, many of which are beyond our control;•other events or factors, including those resulting from global pandemics, such as the COVID-